Atrial Fibrillation Trial, Recruiting NCT07275151 Sponsor: CathVision ApS Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT07275151
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are having their first-ever procedure to isolate the pulmonary veins (the veins connecting the lungs to the heart) as a treatment for atrial fibrillation (an irregular heartbeat condition).
  • People who are male or non-pregnant female, aged 21 years or older.
  • People who are willing and able to sign a consent form before any study-related procedures take place.
  • People whose heart is in a normal, regular rhythm at the time the treatment is applied during the procedure.

Who may not be able to join:

  • People who are pregnant or currently breastfeeding.
  • People who are already taking part in another research study involving an experimental drug or medical device that could interfere with this trial.
  • People whom the doctor running the trial considers unsuitable for participation, for any reason.
  • People who have previously had a heart ablation procedure (a procedure using heat, cold, or electrical energy to treat abnormal heart rhythms).
  • People who have other health conditions, personal circumstances, or psychological factors that, in the treating doctor's opinion, could affect their ability to take part or follow up as required, or could affect the quality of the study results.
  • People whose life expectancy is less than 12 months, in the opinion of the treating doctor.
  • People whom the treating doctor considers to be part of a vulnerable group (confirm with trial site for further detail on how this is defined).
  • People whose heart is unlikely to be in a normal rhythm at the time of the procedure, or who are unlikely to maintain a normal rhythm after an electrical reset of the heart (cardioversion).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +45 31324745

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
CathVision ApS
Registry
ClinicalTrials.gov
Start date
22 July 2026
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pulmonary vein isolation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov